Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy
Jun 13, 2019
— David Caponera Appointed Head of Patient Advocacy and Patient Services —
“We are thrilled to have
Dr. Kates has three decades of experience in the development and
regulation of human therapeutics and life science products. He joins
Mr. Caponera has worked for nearly 25 years as a specialist in patient
advocacy and engagement, both within the pharmaceutical industry and as
an independent consultant. His industry experience includes four years
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include risks relating to Dicerna’s clinical and preclinical research and other risks identified under the heading "Risk Factors" included in the Company’s most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Dicerna™, GalXC™ and PHYOX™ are trademarks of
Stern Investor Relations, Inc.
Lauren Stival, 212-698-8646
Alex Van Rees, 973-442-1555 ext. 111